Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 188 participants.

Also called NCT05167513

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 188 participants (enrolled count) (from the registry)
Sponsor
  • Getz Pharma Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05167513
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Pakistan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05167513. Allocation not applicable; no masking; primary purpose treatment. Start 2021-01-01 (actual); primary completion 2022-04-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients
Acronym
DQOL
Condition
Quality of Life
Condition
Metformin+Sitagliptin
Intervention (Drug)
Metformin / Sitagliptin Oral Tablet
Lead sponsor
Getz Pharma (class: industry)

Record details

Record id
cardio:ct-nct05167513
Content hash
b5aa3e8a7157cd0679e8bf8fdb7b9ec6843e1d470b80740efee0fd7766c822df